The U.S. protein expression market is primarily driven by the factors such as the increasing prevalence of chronic diseases, increasing investment for recombinant protein expression, advancement in technology for expression systems, increasing geriatric population, and robust growth of the life sciences industry in the country.

Request for Free Sample Copy of this Reseach Report at https://www.vynzresearch.com/healthcare/us-protein-expression-market/request-sample

Based on systems, the market is segmented into prokaryotic expression systems, yeast expression systems, cell-free expression systems, mammalian cell expression systems, algal-based expression systems, and insect cell expression systems. Among the various systems being used in the market, the prokaryotic expression system holds the largest share in the U.S. protein expression market.
Based on end users, the market is segmented into academic research institutes, contract research organizations, pharmaceutical and biotechnology companies, and others. Pharmaceutical and biotechnology companies are the largest end user in the U.S. protein expression market.

The increasing prevalence of chronic diseases, increasing funding for recombinant protein expression from government and non-government organizations, advancement in technology for expression systems, increasing geriatric population, and robust growth of the life sciences industry in the country are the primary growth drivers for the U.S. protein expression industry.

Some of the key players operating in the U.S. protein expression market are New England Biolabs, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., Takara Bio Inc., Lonza Group Ltd., Merck KGaA, Promega Corporation, Genscript Biotech Corporation, Agilent Technologies Inc., and Bio-Rad Laboratories, Inc.

Source: VynZ Research